tetano
Editor, Senior Moderator
Clin Infect Dis
. 2022 Aug 29;ciac683.
doi: 10.1093/cid/ciac683. Online ahead of print.
Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial
Manjusha Gaglani[SUP] 1 2 [/SUP], Sara S Kim[SUP] 3 [/SUP], Allison L Naleway[SUP] 4 [/SUP], Min Z Levine[SUP] 3 [/SUP], Laura Edwards[SUP] 5 [/SUP], Kempapura Murthy[SUP] 1 [/SUP], Kayan Dunnigan[SUP] 1 [/SUP], Tnelda Zunie[SUP] 1 [/SUP], Holly Groom[SUP] 4 [/SUP], Sarah Ball[SUP] 5 6 [/SUP], Zuha Jeddy[SUP] 5 [/SUP], Danielle Hunt[SUP] 5 [/SUP], Meredith G Wesley[SUP] 5 [/SUP], Suryaprakash Sambhara[SUP] 3 [/SUP], Shivaprakash Gangappa[SUP] 3 [/SUP], Lauren Grant[SUP] 3 [/SUP], Weiping Cao[SUP] 3 [/SUP], F Liaini Gross[SUP] 3 [/SUP], Margarita Mishina[SUP] 3 [/SUP], Alicia M Fry[SUP] 3 [/SUP], Mark G Thompson[SUP] 3 [/SUP], Fatimah S Dawood[SUP] 3 [/SUP], Brendan Flannery[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Antibody responses to non-egg-based standard-dose cell-culture influenza vaccine (containing 15 µg hemagglutinin (HA)/component) and recombinant vaccine (containing 45 µg HA/component) during consecutive seasons have not been studied in the United States.
Methods: In a randomized trial of immunogenicity of quadrivalent influenza vaccines among healthcare personnel (HCP) aged 18-64 years over two consecutive seasons, HCP who received recombinant-hemagglutinin (RIV) or cell-culture-based vaccine (ccIIV) during the first season (Y1) were re-randomized the second season of 2019-2020 (Y2) to receive ccIIV or RIV, resulting in four ccIIV-RIV combinations. In Y2, hemagglutination inhibition (HI) antibody titers against reference cell-grown vaccine viruses were compared in each ccIIV-RIV group with titers among HCP randomized both seasons to receive egg-based, standard-dose inactivated influenza vaccine (IIV), using geometric mean titer (GMT) ratios of Y2-post-vaccination titers.
Results: Y2 data from 414 HCPs were analyzed per-protocol. Compared to 60 IIV/IIV recipients, 74 RIV/RIV and 106 ccIIV/RIV recipients showed significantly elevated GMT ratios (Bonferroni corrected P <.007) against all components except A (H3N2). Post-vaccination GMT ratios for ccIIV/ccIIV and RIV/ccIIV were not significantly elevated compared to IIV/IIV except for RIV/ccIIV against A(H1N1)pdm09.
Conclusions: In adult HCPs, receipt of RIV two consecutive seasons or the second season was more immunogenic than consecutive egg-based IIV for three of the four components of quadrivalent vaccine. Immunogenicity of ccIIV/ccIIV was similar to that of IIV/IIV. Differences in hemagglutinin antigen content may play a role in immunogenicity of influenza vaccination in consecutive seasons.
Keywords: Flublok® Quadrivalent; Flucelvax® Quadrivalent; Influenza vaccines; healthcare personnel; immunogenicity.
. 2022 Aug 29;ciac683.
doi: 10.1093/cid/ciac683. Online ahead of print.
Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial
Manjusha Gaglani[SUP] 1 2 [/SUP], Sara S Kim[SUP] 3 [/SUP], Allison L Naleway[SUP] 4 [/SUP], Min Z Levine[SUP] 3 [/SUP], Laura Edwards[SUP] 5 [/SUP], Kempapura Murthy[SUP] 1 [/SUP], Kayan Dunnigan[SUP] 1 [/SUP], Tnelda Zunie[SUP] 1 [/SUP], Holly Groom[SUP] 4 [/SUP], Sarah Ball[SUP] 5 6 [/SUP], Zuha Jeddy[SUP] 5 [/SUP], Danielle Hunt[SUP] 5 [/SUP], Meredith G Wesley[SUP] 5 [/SUP], Suryaprakash Sambhara[SUP] 3 [/SUP], Shivaprakash Gangappa[SUP] 3 [/SUP], Lauren Grant[SUP] 3 [/SUP], Weiping Cao[SUP] 3 [/SUP], F Liaini Gross[SUP] 3 [/SUP], Margarita Mishina[SUP] 3 [/SUP], Alicia M Fry[SUP] 3 [/SUP], Mark G Thompson[SUP] 3 [/SUP], Fatimah S Dawood[SUP] 3 [/SUP], Brendan Flannery[SUP] 3 [/SUP]
Affiliations
- PMID: 36031405
- DOI: 10.1093/cid/ciac683
Abstract
Background: Antibody responses to non-egg-based standard-dose cell-culture influenza vaccine (containing 15 µg hemagglutinin (HA)/component) and recombinant vaccine (containing 45 µg HA/component) during consecutive seasons have not been studied in the United States.
Methods: In a randomized trial of immunogenicity of quadrivalent influenza vaccines among healthcare personnel (HCP) aged 18-64 years over two consecutive seasons, HCP who received recombinant-hemagglutinin (RIV) or cell-culture-based vaccine (ccIIV) during the first season (Y1) were re-randomized the second season of 2019-2020 (Y2) to receive ccIIV or RIV, resulting in four ccIIV-RIV combinations. In Y2, hemagglutination inhibition (HI) antibody titers against reference cell-grown vaccine viruses were compared in each ccIIV-RIV group with titers among HCP randomized both seasons to receive egg-based, standard-dose inactivated influenza vaccine (IIV), using geometric mean titer (GMT) ratios of Y2-post-vaccination titers.
Results: Y2 data from 414 HCPs were analyzed per-protocol. Compared to 60 IIV/IIV recipients, 74 RIV/RIV and 106 ccIIV/RIV recipients showed significantly elevated GMT ratios (Bonferroni corrected P <.007) against all components except A (H3N2). Post-vaccination GMT ratios for ccIIV/ccIIV and RIV/ccIIV were not significantly elevated compared to IIV/IIV except for RIV/ccIIV against A(H1N1)pdm09.
Conclusions: In adult HCPs, receipt of RIV two consecutive seasons or the second season was more immunogenic than consecutive egg-based IIV for three of the four components of quadrivalent vaccine. Immunogenicity of ccIIV/ccIIV was similar to that of IIV/IIV. Differences in hemagglutinin antigen content may play a role in immunogenicity of influenza vaccination in consecutive seasons.
Keywords: Flublok® Quadrivalent; Flucelvax® Quadrivalent; Influenza vaccines; healthcare personnel; immunogenicity.